Stoke Therapeutics (STOK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Stoke Therapeutics

NasdaqGS•Healthcare•Biotechnology

$29.81-0.18(-0.01%)Market closed

Market Cap

$1.88B

P/S

68.0x

P/B

5.4x

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

How this company scores

WeakMetricSide Score: 33/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability7/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality9/25

Strengths

Interest easily coveredCash-backed earningsNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 35.7x5y range 7.7x – 35.7x

P/S · 68.0x5y range 2.0x – 276.9x

Currently above its 18-quarter median.

P/B · 5.4x5y range 1.0x – 5.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.88B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $27.59M
Q. Revenue: $9.32M
TTM EBITDA: $-221.63M
TTM Op. Income: $-223.38M
Q. Op. Income: $-65.43M
TTM Net Income: $-207.90M
Q. Net Income: $-61.62M
EPS: $-0.93
Shares Out.: $66.02M

$27.59M in TTM revenue declined 86.2% YoY, reaching $9.32M last quarter. TTM EBITDA of $-221.63M and TTM operating income of $-223.38M show growth is flowing through to the bottom line. However, net income is negative at $207.90M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -696.7%
Op. Margin: -701.7%
Net Margin: -660.8%

Op. margin of -701.7% is down 504.1% YoY — costs are rising relative to revenue. Net margin at -660.8% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 68.0x
P/B Ratio: 5.4x

P/S of 68.0x and P/B of 5.4x. P/S is high, meaning growth expectations are priced in. Across the last 3 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $393.97M
Cash: $110.00M
Long-Term Debt: N/A
Book Value: $345.55M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-56.59M
TTM Free Cash Flow: $-180.68M
FCF Margin: -654.9%
FCF / Net Income: 0.9

TTM FCF of $-180.68M on $-56.59M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 5 consecutive quarters — a weakening trend.